As shown in Figure 3E, lymphodepleting preconditioning potentiated the antitumor efficacy of both CAR T-cell treatments; however, treatment with H9 CAR-IL15 T cells exhibited a better therapeutic effect than treatment with H9 CAR T cells (mean tumor volume on Day 21 post CAR-T injection: 30.8 vs. 351.8 mm3, p < 0.0001; Figure 3F, TGI: 91.2% vs. 40.9%, n = 5 for H9 CAR-IL15 vs. H9 CAR). The gene discussed is IL15; the disease is neoplasm.